UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016312
Receipt number R000018919
Scientific Title Standardization of the MRI scanning method in the diagnosis of N-factor in primary lung cancer
Date of disclosure of the study information 2015/01/23
Last modified on 2023/08/01 16:16:50

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Standardization of the MRI scanning method in the diagnosis of N-factor in primary lung cancer

Acronym

Standardization of the MRI scanning method in the diagnosis of N-factor in primary lung cancer

Scientific Title

Standardization of the MRI scanning method in the diagnosis of N-factor in primary lung cancer

Scientific Title:Acronym

Standardization of the MRI scanning method in the diagnosis of N-factor in primary lung cancer

Region

Japan


Condition

Condition

primary lung cancer

Classification by specialty

Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To compare the diagnostic accuracy of N-factor in primary lung cancer between MRI imaging (DWI MRI, STIR) and FDG-PET/CT at multi-center trial.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The diagnostic accuracy of N-factor (N0/1/2) is compared between MRI imaging (DWI, STIR) and FDG-PET/CT for each referring the pathological diagnosis as gold standards.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients planned for surgery with diagnosis of primary lung cancer or suspected.
2) Aged 20 or older
3) All subjects must be fully informed about the study and give consent
4) The patient who carries out FDG-PET/CT within 2 months scheduled date of surgery.

Key exclusion criteria

1) Patients who was already enrolled in this study
2) Patient of contraindication to an MRI (e.g. after implantation of a pacemaker)
3) Patient who couldn't carry out FDG-PET/CT before the oparation
4) Patient with a history of an operation of primary lung cancer
5) Patient with a history of radiation irradiation to a thorax
6) During medication by diabetes or blood glucose level >=150mg/dL
7) Pregnant, parturient, or breastfeeding women
8) Patients who was diagnosis of small cell lung cancer, a benign tumor, and other nonneoplastic diseases in pathology organizational diagnosis
9) Any others judged ineligible as a subject by the investigator/sub-investigator

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Hidetake
Middle name
Last name Yabuuchi

Organization

Kyusyu University

Division name

Department of Health Sciences

Zip code

812-8582

Address

3-1-1, Maidashi, Higashi-ku, Hukuoka ,812-8582, JAPAN

TEL

092-642-6727

Email

h-yabu@med.kyushu-u.ac.jp


Public contact

Name of contact person

1st name Hidetake
Middle name
Last name Yabuuchi

Organization

Kyusyu University

Division name

Department of Health Sciences

Zip code

812-8582

Address

3-1-1, Maidashi, Higashi-ku, Hukuoka ,812-8582, JAPAN

TEL

092-642-6727

Homepage URL


Email

h-yabu@med.kyushu-u.ac.jp


Sponsor or person

Institute

Kyusyu University

Institute

Department

Personal name



Funding Source

Organization

Bayer Yakuhin

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyushu University

Address

Maidashi, Higashi-ku, Fukuoka

Tel

+81-92-642-6727

Email

h-yabu@med.kyushu-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 01 Month 23 Day


Related information

URL releasing protocol

http://www.radiol.med.kyushu-u.ac.jp/research-info

Publication of results

Unpublished


Result

URL related to results and publications

http://www.radiol.med.kyushu-u.ac.jp/research-info

Number of participants that the trial has enrolled

158

Results

N-stage per patient
There was no significant difference in sensitivity and accuracy between three modalities by two readers.
However, specificity of FDG-PET/CT in reader 2 were superior to those of DWI and STIR in reader 1.
N-stage per LN station
Sensitivity of DWI in reader 2 was superior to that of FDG-PET/CT in reader 2.
Specificity and accuracy of FDG-PET/CT in reader 2 was superior to those of STIR and DWI in both readers.



Results date posted

2023 Year 08 Month 01 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Histopathological diagnosis of primary lesion (n=158)
Adenocarcinoma 124
Squamous cell carcinoma 24
Large cell carcinoma 6
Adenosquamous cell carcinoma 4

Pathological N stage
N0 118
N1 18
N2 21
N3 1
75% (118/158) patients were negative, and 25% (40/158) had positive lymph node metastasis histopathologically.

Participant flow

Registered patients (n=178)

Excluded if
The imaging data was inappropriate (n=9) or impossible to be imported (n=3)

Excluded if
The duration between MRI and PET > 2 months(n=4) or histology is not NSCLC (n=4)

Final cohort (n=158)

Adverse events

N/A

Outcome measures

Diagnostic value per patient and per LN station

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 08 Month 28 Day

Date of IRB

2014 Year 07 Month 01 Day

Anticipated trial start date

2014 Year 08 Month 28 Day

Last follow-up date

2016 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Patients are registered non-selectively.
Patient background, FDG-PET/CT and MR imaging information are recorded, and statistical analysis of the data is carried out.


Management information

Registered date

2015 Year 01 Month 23 Day

Last modified on

2023 Year 08 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018919


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name